BioLineRx Ltd. (NASDAQ:BLRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Several other equities analysts also recently issued reports on BLRX. Maxim Group reissued a “hold” rating and issued a $1.00 target price on shares of BioLineRx in a research report on Wednesday, September 7th. S&P Equity Research cut their target price on BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. Finally, Roth Capital reissued a “buy” rating and issued a $7.00 target price on shares of BioLineRx in a research report on Sunday, August 14th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. BioLineRx presently has a consensus rating of “Buy” and a consensus target price of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) traded down 4.35% during trading on Tuesday, hitting $1.10. The stock had a trading volume of 89,935 shares. The firm has a 50 day moving average price of $1.01 and a 200 day moving average price of $0.92. The firm’s market cap is $62.07 million. BioLineRx has a 12-month low of $0.71 and a 12-month high of $1.73.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.02. On average, equities analysts expect that BioLineRx will post ($0.26) earnings per share for the current fiscal year.

An institutional investor recently raised its position in BioLineRx stock. Menta Capital LLC increased its stake in BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned 0.18% of BioLineRx worth $101,000 at the end of the most recent quarter. 12.46% of the stock is currently owned by hedge funds and other institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.